Neoadjuvant chemoradiotherapy plus PD-1 inhibitor (tislelizumab) for high risk and MRF+ low locally advanced rectal cancer.

Authors: Jiarui Lin, YeZhong Zhuang, Haokai Hu, Lisheng Huang, Jinpeng Yuan, Xiaolong Wei, Muming Xu

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e15644

Source: Full article

---

Abstract

e15644